Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features.
Cancer predisposition syndromes
Childhood cancer
Pathology
Journal
Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
12
11
2020
accepted:
09
02
2021
pubmed:
27
2
2021
medline:
27
1
2022
entrez:
26
2
2021
Statut:
ppublish
Résumé
In children with cancer, specific clinical features such as physical anomalies, occurrence of cancer in young relatives, specific cancer histologies, and unique mutation/methylation signatures may indicate the presence of an underlying cancer predisposition syndrome (CPS). The proportion of children with a cancer type suggesting a CPS among all children with cancer is unknown. To determine the proportion of children with cancer types suggesting an underlying CPS among children with cancer. We evaluated the number of children with cancer types strongly associated with CPS diagnosed in Germany between 2007 and 2016. Data were obtained from various sources including two national pediatric pathology reference laboratories for brain and solid tumors, respectively, various childhood cancer trial offices as well as the German Childhood Cancer Registry. Among 21,127 children diagnosed with cancer between 2007 and 2016, 2554 (12.1%) had a cancer type strongly associated with a CPS. The most common diagnoses were myelodysplastic syndrome and juvenile myelomonocytic leukemia, retinoblastoma, malignant peripheral nerve sheath tumor, infantile myofibromatosis, medulloblastoma
Identifiants
pubmed: 33634344
doi: 10.1007/s10689-021-00234-4
pii: 10.1007/s10689-021-00234-4
pmc: PMC8484228
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-277Informations de copyright
© 2021. The Author(s).
Références
PLoS Genet. 2018 Jun 18;14(6):e1007399
pubmed: 29912901
Nat Rev Dis Primers. 2019 Feb 14;5(1):11
pubmed: 30765705
PLoS One. 2018 Dec 13;13(12):e0208936
pubmed: 30543698
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
J Med Genet. 2018 Dec;55(12):785-793
pubmed: 30287599
Int J Cancer. 2019 Aug 15;145(4):941-951
pubmed: 30694527
Pediatr Blood Cancer. 2018 Dec;65(12):e27390
pubmed: 30117275
Leukemia. 2017 Dec;31(12):2807-2814
pubmed: 28443606
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Pediatr Blood Cancer. 2006 Nov;47(6):811-8
pubmed: 16317745
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Eur J Cancer. 2017 Jul;80:48-54
pubmed: 28544908
N Engl J Med. 2019 May 9;380(19):1834-1842
pubmed: 31067372
Am J Med Genet A. 2017 Apr;173(4):1017-1037
pubmed: 28168833
Eur J Med Genet. 2016 Mar;59(3):116-25
pubmed: 26825391
Lancet Child Adolesc Health. 2019 May;3(5):322-331
pubmed: 30885698